Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Advanced Financial Summary 
Rowena Amene farkas
Mar 29, 2024 10:53AM ET
Ranged
0
0
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
13.000
+0.790
+6.47%
Pre Market
13.000
0.000
0.000%
6:23:22 - Real-time Data
Type:
Equity
Market:
United States
- Volume: 73,221
- Bid/Ask: 0.000 / 0.000
- Day's Range: 12.330 - 13.690
Avalo Therapeutics
13.000
+0.790
+6.47%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Financial Summary
- Income Statement
- Balance Sheet
- Cash Flow
- Ratios
- Dividends
- Earnings
NASDAQ:AVTX Financials
A brief overview of the NASDAQ:AVTX financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Avalo Therapeutics Inc over time.
Avalo Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 1.92 million compared to USD 18.05 million a year ago. Net loss was USD 31.54 million compared to USD 41.66 million a year ago.
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter
AVTX Income Statement
Gross margin TTM -417.05%
Operating margin TTM -1,218.5%
Net Profit margin TTM -1,639.5%
Return on Investment TTM 0%
Total Revenue Net Income
| Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|
| Total Revenue | 0.571 | 0.236 | 0.643 | 0.475 |
| Gross Profit | 0.147 | -0.004 | -3.66 | -4.51 |
| Operating Income | -3.75 | -3.75 | -7.15 | -8.79 |
| Net Income | -8.17 | -5.23 | -8.19 | -9.96 |
AVTX Balance Sheet
Quick Ratio MRQ 1.61
Current Ratio MRQ 1.82
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 26.05%
Total Assets Total Liabilities
| Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|
| Total Assets | 20.99 | 29.27 | 24.24 | 36.24 |
| Total Liabilities | 13.69 | 14.58 | 31.2 | 42.5 |
| Total Equity | 7.3 | 14.7 | -6.97 | -6.27 |
AVTX Cash Flow Statement
Cash Flow/Share TTM -38.27
Revenue/Share TTM 2.4
Operating Cash Flow -59.96%
Cash Net Change in Cash
| Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|
| Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
| Cash From Operating Activities | -2.77 | -6.84 | -11.03 | -10.05 |
| Cash From Investing Activities | 0 | 0 | 0 | -0.133 |
| Cash From Financing Activities | 0.001 | 10.7 | 0.598 | 13.75 |
| Net Change in Cash | -2.76 | 3.86 | -10.43 | 3.56 |
* In Millions of USD (except for per share items)
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Write your thoughts about Avalo Therapeutics Inc
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Pepe Vega
Mar 27, 2024 5:09PM ET
Acquisition will cost almost $20 million cash out (mostly to advisors) and huge dilution in future to pay for those first dosages of TRIALS! AND the warrants and stock granted. this over tripling is sbdurdly injustigied and will cost very dearly to those who paid north of 10...
1
0
AIKanak
Dec 19, 2023 2:54PM ET
Company does not have working a=capital and reverse split wiill slow down liquidity flow. The comoany is doomed. CEO is saying if reverse split is not appo=roved the company will have to sell its property. Which meens inestors will lose thier money. Beware! investors, AVTX is a junk equity. Period!
0
1
AIKanak
Dec 19, 2023 2:36PM ET
Tomorrow if reverse split gets the votes, then its stock is done for. It will tumble like a pillar of sand. Analyst are already rating it for strong sell. You better take your money and run!
0
0
Basel haddadin
Sep 14, 2023 11:35AM ET
will close at 0.30
1
4
SS SS
Jul 21, 2020 6:01PM ET
any opinion for CERC ? will go up to 5$ soon ?
2
2
SS SS
Jun 16, 2020 4:40AM ET
any precious idea what will happen with CERC please ?
1
1
Marco Furlan
Jun 16, 2020 4:40AM ET
They Will have a virtuale encounter with potential investor on 06/ 01/2022, After tomorrow. They probably Will talk about two new drugs they presented FDA , the result of their studies and FDA position. If everithing Is positive the stock might grow .
0
0
Ubaldo Piazza
Jun 16, 2020 4:40AM ET
Tu che ne pensi sarà positivo o no?
0
0
SS SS
Jun 13, 2020 3:38AM ET
is it worths to entry right now ? what do you think folks ?
0
0
Michael Hobson
Jul 10, 2017 10:45AM ET
$5 stock by November 15th, 2017
0
0
Jeshua Haskins
Jul 10, 2017 10:45AM ET
Possibly more, if they announce good news in conjunction with the positive news they announced earlier this year with CERC-301. FDA already intends to fast track the approval for the MDD drug.
1
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review